Nova Semaglutide: Understanding the Medicine Behind the Name

What 'nova semaglutide' actually refers to — and why the distinction matters

There is no licensed UK medicine called "nova semaglutide". The name circulates online as shorthand for semaglutide products broadly, sometimes reflecting brand confusion, sometimes the result of search engines blending terms. The semaglutide products that exist in the UK are Wegovy (weight management) and Ozempic (type 2 diabetes) — both made by Novo Nordisk. A common misconception worth clearing up gently: Ozempic and Wegovy contain the same molecule, but they carry different licensed indications and different dose ceilings. Using one in place of the other is not a clinical shortcut; it is a prescribing decision with real implications for safety and effectiveness.

If you arrived here researching semaglutide for weight loss, the relevant product is Wegovy. The Wegovy overview on our site covers the injection's licensed use, dose schedule and what to expect in more detail. The underlying pharmacology is the same across the Wegovy range: semaglutide mimics a gut hormone called GLP-1, signalling fullness to the brain and moderating gastric emptying. That mechanism is why the side-effect profile is predominantly gastrointestinal, and why dose titration is gradual.

Understanding which product applies to your situation is the first part of the decision. The second is whether semaglutide, as opposed to the dual-agonist tirzepatide, is the right fit. Both are licensed for weight management in the UK, and a prescriber can help you think through the comparison based on your health history.

Whether semaglutide is licensed for your situation

Wegovy is licensed for adults with a BMI of 30 or above, or a BMI of 27 or above alongside at least one weight-related condition such as high blood pressure, raised cholesterol, prediabetes, type 2 diabetes or obstructive sleep apnoea. Lower BMI thresholds apply for people from South Asian, Chinese, Middle Eastern, Black African or African-Caribbean backgrounds under UK clinical guidance. NICE's appraisal of semaglutide (TA875) sets out the NHS eligibility framework, which adds further conditions around specialist services and a two-year treatment cap.

Private prescribing follows the licensed SmPC criteria rather than NICE's NHS-specific pathway, which means BMI and comorbidity profile remain the clinical anchors, but the additional NHS service requirements do not apply. That said, a BMI that meets the threshold on paper is not an automatic green light. A prescriber looks at the full picture: current medicines, cardiovascular history, kidney function, any personal or family history of thyroid conditions, and more. Pregnancy, breastfeeding and the period leading up to a planned pregnancy are situations where semaglutide is not recommended. The same applies to anyone under 18.

For a fuller look at how these factors interact in a private consultation, our weight-loss treatment overview explains what the clinical assessment involves and what happens at each stage.

What the evidence says about results, and what shapes them

The STEP 1 trial, published in the New England Journal of Medicine, followed adults with obesity or overweight plus a weight-related condition over 68 weeks. Participants using semaglutide 2.4 mg alongside lifestyle changes lost around 15% of body weight on average. That figure comes from a controlled trial setting; individual results vary depending on adherence, diet, activity and other health factors.

The 7.2 mg dose, approved by the MHRA in early 2026, produced approximately 20.7% average weight loss over 72 weeks in trial data, a meaningful step up, and one that narrows the gap with the highest doses of tirzepatide. If you are already established on semaglutide and curious about what the newer options mean for ongoing treatment, that is a conversation to have at your next clinical review rather than a change to make independently. Details on semaglutide dosing and titration give more context on how dose increases are managed, and if you want to look further ahead, our page on semaglutide 3 covers what comes next in the treatment journey.

Results also depend heavily on what happens around the injection. Semaglutide reduces appetite substantially, but that reduced intake needs to be nutritionally adequate (enough protein, fibre and hydration) and pairing treatment with some form of physical activity helps preserve muscle mass. A prescriber or dietitian can help map that out for your particular circumstances. Worth knowing: the appetite reduction many people experience in the first few weeks is not the plateau; it tends to deepen as doses increase.

How to take the next step without cutting corners

Semaglutide is available in the UK only on prescription, and the supply chain matters more than most people realise. The MHRA has seized counterfeit weight-loss pens (including fakes that contained insulin rather than the labelled medicine) and warned publicly about sellers operating without a clinical assessment. Any legitimate route to Wegovy involves a prescriber reviewing your health history, verifying your identity and weight, and making a documented clinical decision. If a seller is offering semaglutide without that process, that is the signal to stop.

You can verify any online pharmacy on the GPhC pharmacy register before sharing any personal or medical information. At nume, every consultation is reviewed personally by a GPhC-registered Independent Prescriber on the same day, a real clinician, reading your answers, not software running a checkbox. Our pharmacy's registration number is 9012878, verifiable directly on the register.

If you have questions before starting, our FAQs cover the most common ones. For anything more specific, our team is reachable seven days a week. When you are ready to find out whether semaglutide is suitable for you, speak to our prescribers through a free consultation at our weight-loss treatments page.